4.7 Article

Clinical picture and treatment of 2212 patients with common variable immunodeficiency

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 134, Issue 1, Pages 116-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.12.1077

Keywords

Common variable immunodeficiency; immunoglobulin replacement; patient self-reported outcomes; quality of life; primary antibody deficiency; autoimmunity; enteropathy; granulomas; lymphadenopathy; treatment

Funding

  1. PPTA Europe
  2. CSL Behring UK
  3. German Federal Ministry of Education and Research [BMBF 01 EO 0803, BMBF 1315883]
  4. DZIF project [TTU 04.802]
  5. EU [HEALTH-F2-2008-201549]
  6. German BMBF [01GM0896]
  7. National Institute of Health Research of the UK, Cambridge Biomedical Centre
  8. Great Ormond Street Hospital Children's Charity
  9. Jeffrey Modell Foundation
  10. Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
  11. French Ministry of Health
  12. French association of patients with PID (IRIS)
  13. LFB
  14. Baxter Biosciences
  15. CSL Behring
  16. Octapharma
  17. Pfizer
  18. Orphan Europe
  19. Binding Site
  20. [DZIF TTU-IICH 07.801]

Ask authors/readers for more resources

Background: Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high variability in clinical presentation. The main features include respiratory tract infections and their associated complications, enteropathy, autoimmunity, and lymphoproliferative disorders. Objective: This study analyzes the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe. Methods: Data on 2212 patients with CVID from 28 medical centers contributing to the European Society for Immunodeficiencies Database were analyzed retrospectively. Results: Early disease onset (< 10 years) was very frequent in our cohort (33.7%), especially in male subjects (39.8%). Male subjects with early-onset CVID were more prone to pneumonia and less prone to other complications suggesting a distinct disease entity. The diagnostic delay of CVID ranges between 4 and 5 years in many countries and is particularly high in subjects with early-onset CVID. Enteropathy, autoimmunity, granulomas, and splenomegaly formed a set of interrelated features, whereas bronchiectasis was not associated with any other clinical feature. Patient survival in this cohort was associated with age at onset and age at diagnosis only. There were different treatment strategies in Europe, with considerable differences in immunoglobulin dosing, ranging from 130 up to 750 mg/kg/mo. Patients with very low trough levels of less than 4 g/L had poor clinical outcomes, whereas higher trough levels were associated with a reduced frequency of serious bacterial infections. Conclusion: Patients with CVID are being managed differently throughout Europe, affecting various outcome measures. Clinically, CVID is a truly variable antibody deficiency syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available